To substantiate these conclusions, we selected 12 lung cancer patients undergoing anti-PD-1 therapy from the Nanjing Drum Tower Hospital for a follow-up study, and confirmed that patients with high ISG15 expression were more responsive to anti-PD-1 therapy (Fig. 7C, D). This evidence concerns the gene PDCD1 and lung carcinoma.